Literature DB >> 8542893

The use of thallium-201 in the preoperative detection of breast cancer: an adjunct to mammography and ultrasonography.

M Cimitan1, R Volpe, E Candiani, G Gusso, R Ruffo, E Borsatti, S Massarut, C Rossi, S Morassut, A Carbone.   

Abstract

Thallium-201 breast scans were performed preoperatively in 72 female patients with breast abnormalities detected by mammography and/or ultrasonography (7.5-13 MHz), in order to differentiate benign from malignant breast disease. Informed consent was obtained from each patient. Scintigraphy consisted of anterior and oblique planar images of the affected breast and axilla at 10 min and 3 h following the injection of 201Tl chloride (110 MBq). All 201Tl scans were interpreted without prior knowledge of surgery data. Pathological features of breast malignancies, such as tumour size, axillary lymph node metastases, tumour grading, lymphatic vascular channel invasion and receptor status, were analysed for their association with 201Tl uptake by tumour cells. A total of 76 breast lesions were assessed in the study. On final histological diagnosis, there were 56 malignant tumours, 14 benign nodules (9 fibroadenomas, two cases of adenosis, two cases of focal fibrosis and one case of epitheliosis) and six atypical lesions (atypical ductal or lobular hyperplasia). Thallium scintigraphy was shown to have high accuracy (92%) in detecting breast cancer, better than mammography (74%) and ultrasonography (84%). Almost all (51/56) breast cancers showed greater 201Tl activity than surrounding normal breast tissue while there was no significant increase in 201Tl activity above background in all but one (19/20) case of non-malignant disease. 201Tl activity within breast tumours, calculated as tumour/background (T/B) ratio, ranged between 1.2 and 2.5 with a mean value of 1.45. In our experience the concentration of thallium in the breast cancer seems to be primarily dependent on vascularity and tumour size rather than tumour grading, lymphatic/vascular invasion or receptor status. 201Tl scan sensitivity was 97% for malignant lesions larger than 1.5 cm (n = 35) and 80% for lesions of 1.5 cm or less (n = 21); however, five of the eight breast cancers smaller than 1.0 cm were also detectable by 201Tl scintigraphy, compared with five out of seven by mammography. Thallium scintigraphy would not be useful in evaluating the axilla for lymph node metastases (sensitivity 27%, specificity 77%).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8542893     DOI: 10.1007/bf00800591

Source DB:  PubMed          Journal:  Eur J Nucl Med        ISSN: 0340-6997


  18 in total

Review 1.  201Tl as a tumour-localizing agent: current status and future considerations.

Authors:  A H Elgazzar; M Fernandez-Ulloa; E B Silberstein
Journal:  Nucl Med Commun       Date:  1993-02       Impact factor: 1.690

2.  201Tl scintigraphy in the staging of lung cancer, breast cancer and lymphoma.

Authors:  A M Sehweil; J H McKillop; R Milroy; M A Sayed; G Ziada; S W Banham; K G Davidson; A Ragib; Y T Omar; H M Abdel-Dayem
Journal:  Nucl Med Commun       Date:  1990-04       Impact factor: 1.690

3.  Nonpalpable breast lesions: accuracy of prebiopsy mammographic diagnosis.

Authors:  G Hermann; C Janus; I S Schwartz; B Krivisky; S Bier; J G Rabinowitz
Journal:  Radiology       Date:  1987-11       Impact factor: 11.105

4.  A prospective study of the development of breast cancer in 16,692 women with benign breast disease.

Authors:  C L Carter; D K Corle; M S Micozzi; A Schatzkin; P R Taylor
Journal:  Am J Epidemiol       Date:  1988-09       Impact factor: 4.897

5.  A complementary role for thallium-201 scintigraphy with mammography in the diagnosis of breast cancer.

Authors:  V W Lee; E J Sax; D B McAneny; S Pollack; R A Blanchard; R M Beazley; M T Kavanah; R J Ward
Journal:  J Nucl Med       Date:  1993-12       Impact factor: 10.057

6.  Delayed diagnosis of breast cancer as a result of normal mammograms.

Authors:  B D Mann; A E Giuliano; L W Bassett; M S Barber; W Hallauer; D L Morton
Journal:  Arch Surg       Date:  1983-01

7.  Thallium scintigraphy in the evaluation of mass abnormalities of the breast.

Authors:  A D Waxman; L Ramanna; L D Memsic; C E Foster; A W Silberman; S H Gleischman; R J Brenner; M B Brachman; C J Kuhar; J Yadegar
Journal:  J Nucl Med       Date:  1993-01       Impact factor: 10.057

8.  Biodistributions of 201Tl in tumor bearing animals and inflammatory lesion induced animals.

Authors:  A Ando; I Ando; M Katayama; S Sanada; T Hiraki; H Mori; N Tonami; K Hisada
Journal:  Eur J Nucl Med       Date:  1987

9.  Clinical evaluation of tumor imaging with 201 TI chloride.

Authors:  K Hisada; N Tonami; T Miyamae; Y Hiraki; T Yamazaki; T Maeda; M Nakajo
Journal:  Radiology       Date:  1978-11       Impact factor: 11.105

10.  Breast carcinomas detected by thallium-201 scintigraphy.

Authors:  M Sluyser; C A Hoefnagel
Journal:  Cancer Lett       Date:  1988-06-15       Impact factor: 8.679

View more
  6 in total

1.  Primary breast cancer imaging with technetium-99m sestamibi and its relation with P-glycoprotein overexpression.

Authors:  J L Moretti; H Azaloux; D Boisseron; J C Kouyoumdjian; J Vilcoq
Journal:  Eur J Nucl Med       Date:  1996-08

2.  Scintimammography with technetium-99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases.

Authors:  L Mansi; P F Rambaldi; E Procaccini; F D Gregorio; A Laprovitera; B Pecori; W D Vecchio
Journal:  Eur J Nucl Med       Date:  1996-08

Review 3.  Use of tomographic nuclear medicine procedures, SPECT and pinhole SPECT, with cationic lipophilic radiotracers for the evaluation of axillary lymph node status in breast cancer patients.

Authors:  Giuseppe Madeddu; Angela Spanu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-15       Impact factor: 9.236

Review 4.  FDG PET and other imaging modalities in the primary diagnosis of suspicious breast lesions.

Authors:  K Scheidhauer; C Walter; M D Seemann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-05-06       Impact factor: 9.236

5.  Generalizable EHR-R-REDCap pipeline for a national multi-institutional rare tumor patient registry.

Authors:  Sophia Z Shalhout; Farees Saqlain; Kayla Wright; Oladayo Akinyemi; David M Miller
Journal:  JAMIA Open       Date:  2022-01-07

6.  Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging.

Authors:  Liza Lindenberg; Anish Thomas; Stephen Adler; Esther Mena; Karen Kurdziel; Julia Maltzman; Bruce Wallin; Kimberly Hoffman; Ira Pastan; Chang Hum Paik; Peter Choyke; Raffit Hassan
Journal:  Oncotarget       Date:  2015-02-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.